Pet Cancer Therapeutics Market to hit USD 760 million by 2030, says Global Market Insights Inc.
August 16, 2022 03:15 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Aug. 16, 2022 (GLOBE NEWSWIRE) -- The pet cancer therapeutics market value is anticipated to be valued over USD 760 million by 2030. Rising awareness pertaining to pet diseases...
Immuno-Oncology Drug Development Analytical Tool 2022: 1260 Companies/Partners Who are Developing 3,896 I-O Drugs Where of 2,948 are in Active Development in Cancer Across 629 Different Targets
May 26, 2022 06:28 ET
|
Research and Markets
Dublin, May 26, 2022 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Drug Development: Analytical Tool" report has been added to ResearchAndMarkets.com's offering. Immuno-Oncology Drug Development:...
Next Generation Complement Therapeutics Markets, 2035
April 04, 2022 10:08 ET
|
Research and Markets
Dublin, April 04, 2022 (GLOBE NEWSWIRE) -- The "Next Generation Complement Therapeutics Market: Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of...
Neoantigens Market Size ($10,54,783.54 Thousand by 2028) Growth Forecast at 31.2% CAGR During 2023 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com
October 07, 2021 10:16 ET
|
The Insight Partners
New York, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Neoantigens Market: Key InsightsAccording to our new research study on “Neoantigens Market to 2028 – Global Analysis and Forecast – by Treatment and...
GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients
August 24, 2020 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Aug. 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases...
AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
August 11, 2020 16:01 ET
|
AzurRx BioPharma, Inc.
Data from first five patients demonstrate positive results with primary efficacy and secondary safety endpoints achievedClinically meaningful improvement (>80%) in coefficient of fat absorption...
India Globalization Capital’s CEO to Speak at CEO Healthcare Symposium in NY on February 12 & 13
February 12, 2018 08:00 ET
|
ram mukunda
BETHESDA, Md., Feb. 12, 2018 (GLOBE NEWSWIRE) --
India Globalization Capital, Inc. (NYSE-MKT:IGC) announced today that Ram Mukunda will be a speaker at the upcoming CEO Healthcare Symposium...
Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma
September 07, 2017 08:10 ET
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
IGC Provides Update on Phytocannabinoid IP Portfolio
November 02, 2016 09:32 ET
|
India Globalization Capital
BETHESDA, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT:IGC) announces updates for five patents related to method and treatment of pain, seizures and eating...
IGC Announces Financial Results for Fiscal Year Ended March 31, 2016
July 18, 2016 08:30 ET
|
India Globalization Capital
BETHESDA, Md., July 18, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT:IGC) announces financial results for the fiscal year ended March 31, 2016. Total revenue was...